Description
Seeking men and women 18 years of age and older who have chronic myeloid leukemia (CML) in chronic phase (CP) with and without the T315I mutation, to determine how well the treatment with asciminib works compared to previously used therapies.
Overview
Participants in this study will receive either a low, mid or high dose of the drug asciminib. There will be about 22 different study visits over 80 weeks.
What we're hoping for
To find out if the drug asciminib is safe and has beneficial effects in people who have chronic myeloid leukemia (CML) in chronic phase (CP) with and without the T315I mutation.
Additional Information
ClinicalTrials.gov Identifier: NCT04666259